Voices
Christof Vulsteke: KEYNOTE-905/EV303 Trial Opens New Era in Bladder Cancer Treatment
Christof Vulsteke/mariamiddelares.be

Christof Vulsteke: KEYNOTE-905/EV303 Trial Opens New Era in Bladder Cancer Treatment

Christof Vulsteke, Medical Oncologist at AZ Maria Middelares and Guest Professor at Universiteit Antwerpen, shared a post on LinkedIn:

“Following our transformative study results in metastatic urothelial cancer (EV302, NEJM2024), we are once again entering a new era in bladder cancer treatment. We just published the remarkable results of the KEYNOTE-905/EV303 trial in the New England Journal of Medicine– a reflection of the power of teamwork across five continents, 242 sites, and 27 countries.

At 2 years:

  • Event free survival 74.7% in the enfortumab vedotin-pembrolizumab group and 39.4% in the control group (HR 0.4)
  • Overall survival 79.7% in the enfortumab vedotin-pembrolizumab group and 63.1% in the control group (HR 0.5)
  • Pathological complete response in 57.1% in the enfortumab vedotin-pembrolizumab group and 8.6% in the control group

Thanks to the patients, my dream team of the clinical trial oncology and all the investigators and co-authors!”

Title: Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

Authors: Christof Vulsteke, Nabil Adra, Pongwut Danchaivijitr, Maksym Sabadash, Alejo Rodriguez-Vida, Zhentao Zhang, Vagif Atduev, Y. Emre Göger, Steffen Rausch, Seok-Ho Kang, Yohann Loriot, Jens Bedke, Matthew D. Galsky, Peter H. O’Donnell, Gunhild von Amsberg, Nimira Alimohamed, Grzegorz Sulimka, Shilpa Gupta, Viktor Paramonov, Keita Nakane, Michael Mihm, Changting Meng, Caizhi David Huang, Chethan Ramamurthy, Blanca Homet Moreno, Anders Ullén

Christof Vulsteke: KEYNOTE-905/EV303 Trial Opens New Era in Bladder Cancer Treatment
Read the Full Article.

KEYNOTE-905/EV-303 Trial: Perioperative Enfortumab Vedotin and Pembrolizumab in Muscle-Invasive Bladder Cancer

Christof Vulsteke: KEYNOTE-905/EV303 Trial Opens New Era in Bladder Cancer Treatment

Alejo Rodriguez-Vida Anders Ullén Blanca Homet Moreno Caizhi David Huang cancer Changting Meng Chethan Ramamurthy Christof Vulsteke Grzegorz Sulimka Gunhild von Amsberg Jens Bedke Keita Nakane Maksym Sabadash Matthew D. Galsky Michael Mihm Nabil Adra NEJM Nimira Alimohamed OncoDaily Oncology Peter H. O'Donnell Pongwut Danchaivijitr Seok-Ho Kang Shilpa Gupta Steffen Rausch Vagif Atduev Viktor Paramonov Y. Emre Göger Yohann Loriot Zhentao Zhang